Janus kinase inhibitors: A new therapeutic option for autoimmune diseases

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

Hashmi Vida; Ahmadpour Mohammad; Mehran Far Sahar; Shiri Haris Reza; Hosseini Arezoo

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: Studies in Medical Sciences Year:2024 | Volume:34 | Issue:12 Page(s): 794-815

Download Full-Text

Persian Verion

View:

Download:

Cites:

Information Journal Paper

Title

Janus kinase inhibitors: A new therapeutic option for autoimmune diseases

Author(s)

Keywords

JAK/STAT moleculesQ4

Janus kinase inhibitorsQ4

Autoimmune diseasesQ4

Abstract

Many cytokines are crucial drivers of cancers and autoimmune conditions. These proteins bind to receptors and signal their responses through Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathways. Genetic variations in the JAK–STAT pathway are correlated with the increased risk of cancers, autoimmunity as well as inflammatory diseases. Targeting JAKs and STATs can be a safe and efficacious strategy for treating these diseases. Tofacitinib, as the first JAK inhibitor, is approved for rheumatoid arthritis therapy. Also, many other JAK inhibitors have been proven or are in various phases of clinical trials for various diseases. At present, small‐molecule JAK inhibitors are considered as a novel category of drugs in the treatment of cancer and immune‐mediated diseases.

Cites

No record.

References

No record.

Cite

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops